SARAH DYCKMAN: Open Payments
NPI 1871011650 · SALEM, OR. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$754 in 38 payments from 16 companies in 2025. Trend: 2023 $698 · 2024 $530 · 2025 $754
Food & beverage: $754
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. | 12 | $160 |
| AstraZeneca Pharmaceuticals LP | 4 | $79 |
| Mallinckrodt Hospital Products Inc. | 2 | $66 |
| JAZZ PHARMACEUTICALS INC. | 2 | $60 |
| Merck Sharp & Dohme LLC | 3 | $59 |
| Regeneron Healthcare Solutions, Inc. | 3 | $52 |
| Actelion Pharmaceuticals US, Inc. | 2 | $43 |
| GENZYME CORPORATION | 2 | $36 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $35 |
| United Therapeutics Corporation | 1 | $33 |
Products named: NUCALA, DUPIXENT, XYWAV, ZERBAXA, TRELEGY ELLIPTA, TERLIVAZ, BREZTRI, GLASSIA.
Industry payments across OR — which companies pay providers there.
